


Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice

Edaire Cheng

**Current Treatment Options in
Gastroenterology**

ISSN 1092-8472

Curr Treat Options Gastro
DOI 10.1007/s11938-014-0041-8



Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice

Edaire Cheng, MD

Address

^{*†}Esophageal Diseases Center, Pediatric Gastroenterology, Department of Pediatrics, Children's Medical Center and the University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA

Email: edaire.cheng@utsouthwestern.edu

²Esophageal Diseases Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

© Springer Science+Business Media, LLC 2015

This article is part of the Topical Collection on *Esophagus*

Keywords Gastroesophageal reflux disease · Eosinophilic esophagitis · Proton pump inhibitors · PPI-responsive esophageal eosinophilia · Topical steroids · Dietary therapy

Opinion statement

New developments in eosinophilic esophagitis (EoE) pathogenesis are shaping our current therapeutic and management strategies. EoE is a chronic allergic inflammatory disease with progression to fibrostenotic disease. The disease warrants early diagnosis and long-term maintenance therapy. The diagnosis of EoE should be based on the concept of an allergy-mediated disease with esophageal dysfunction and esophageal eosinophilia. Recent findings suggest that proton pump inhibitor (PPI)-responsive esophageal eosinophilia (PPI-REE) is likely a continuum of EoE or a similar T-helper 2 (Th2)-mediated allergic process. PPIs have therapeutic properties that can benefit both gastroesophageal reflux disease (GERD) and EoE. Therefore, PPIs should be considered not a diagnostic tool but, rather, a therapeutic option for EoE. If patients are PPI nonresponsive, then dietary therapy or steroid therapy should be considered. Dilation can be reserved as adjuvant therapy for severe fibrostenotic lesions.

Introduction

Eosinophilic esophagitis (EoE) has emerged with increasing incidence globally over the past two decades. EoE is characterized as a chronic inflammatory disease incited by allergens, resulting in esophageal eosinophilia

and severe esophageal dysfunction [1]. This disease afflicts children and adults, causing symptoms of dysphagia and abdominal pain. Over a period of 20 years, great research effort has been made to elucidate the

pathogenesis and natural progression of the disease in order to establish well-defined diagnostic criteria, develop therapeutic options, and generate strategies to monitor the disease. Experts reached a consensus defining EoE as an “immune/antigen-mediated” clinicopathological disease, requiring both esophageal dysfunction and eosinophilia (≥ 15 eosinophils per high-power field [eos/hpf] on one or more biopsy specimens) [1]. With the emergence of proton pump inhibitor (PPI)-responsive esophageal eosinophilia (PPI-REE), experts

advocated the use of acid suppression as a diagnostic tool to exclude EoE. The recommended first-line therapies consisted of dietary therapy or corticosteroid therapy with the goal of achieving symptom resolution and maintaining histological remission. Several advances in elucidating EoE pathogenesis have now reshaped the landscape of EoE therapy. This paper highlights recent findings in EoE pathogenesis and discusses current and investigational therapeutic options in light of the current understanding of EoE.

EoE, PPI-responsive esophageal eosinophilia, and GERD

The overlapping features of EoE and gastroesophageal reflux disease (GERD) pose several challenges in the diagnosis of EoE. Early authorities deemed it crucial to distinguish this disorder from GERD [2]. However, GERD and EoE are not mutually exclusive disorders [3]. First, GERD, in the absence of EoE, can involve mild esophageal eosinophilia. Acid and bile can upregulate adhesion molecules and chemoattractants involved in eosinophil trafficking. Second, if GERD and EoE are unrelated, then the two diseases should coexist by chance alone, given the GERD prevalence of 10–20 % [4]. Third, EoE might contribute to GERD. EoE inflammation and remodeling can alter esophageal motility, delay acid clearance, and reduce lower esophageal sphincter pressure. Disrupted barrier function and increased permeability due to EoE inflammation may render the epithelium susceptible and hypersensitive to acid reflux injury. In fact, vagal sensory neurons have enhanced acid responsiveness in guinea pigs with EoE [5], and acid hypersensitivity has been described in EoE patients [6]. Conversely, GERD might contribute to EoE. Disrupted barrier function due to acid-related injury may increase epithelial permeability to allergens. In addition, refluxed gastric material induces mediators in the epithelium that can exacerbate immune activity [7].

Previously, experts proposed using a PPI trial to distinguish GERD from EoE [2]. This proposal was based on the assumption that acid suppression is the only therapeutic effect of PPIs, and therefore only GERD can respond to PPIs. The assumption has several flaws. First, there are multiple mechanisms whereby EoE patients might benefit from PPI-induced acid suppression (see below). Second, PPIs have acid-independent, anti-inflammatory effects that might benefit both GERD and EoE patients (see below). Indeed, this assumption was questioned as emerging reports described patients with PPI-REE [1, 8–11]. These patients have clinical and histological findings consistent with EoE, yet they achieve clinicohistological remission on PPIs. Prospective studies estimated that 33–74 % of patients with esophageal eosinophilia responded to PPIs [8–11]. Two randomized controlled trials (RCTs) compared esomeprazole 40 mg daily with fluticasone 440 μ g twice daily and found no differences in remission rates [8, 10]. No clinical features, endoscopic features, or inflammatory markers (eotaxin-3, major basic protein, tryptase) can distinguish PPI-REE patients from EoE patients [11, 12]. Most recently, genetic transcriptome

analysis of PPI-REE patients and EoE patients has revealed a remarkable overlapping molecular signature [13••]. Taken together, patients with PPI-REE might indeed have EoE or the same allergy-mediated process that responds to the therapeutic effects of PPIs.

PPIs as a therapeutic option for EoE

There are multiple plausible mechanisms whereby EoE patients benefit from PPI-induced acid suppression [3]. Reducing acid exposure might decrease acid injury-related cytokines, pain, and esophageal permeability. In fact, mucosal integrity, determined by electrical tissue impedance and transepithelial electrical resistance, was impaired in both EoE and PPI-REE patients [14]. Treatment with a high-dose PPI partially restored mucosal integrity in the PPI-REE group. The investigators speculated that acid reflux might exacerbate mucosal permeability, facilitating allergen entry.

EoE patients might benefit from PPIs through mechanisms that are independent of acid suppression. PPIs can inhibit T-helper 2 (Th2) cytokine-induced eotaxin-3 secretion in esophageal epithelial cells, potentially reducing eosinophil recruitment [15•, 16]. The effect was achieved with physiological doses of omeprazole [16]. More recently, eotaxin-3 expression by epithelial cells in esophageal biopsies from children with esophageal eosinophilia was examined before and after PPI therapy [17]. After PPI therapy, eotaxin-3 expression decreased in the proximal esophagus, where reflux is unlikely to occur, suggesting that anti-inflammatory effects, rather than acid suppression, are the reason for the decrease [17]. PPIs can also exhibit antioxidant properties, inhibit certain functions of immune cells, and decrease expression of adhesion molecules and inflammatory cytokines [3]. Lastly, timely transcriptome analysis of PPI-REE patients showed reversion of classic allergic inflammation gene expression, including eosinophilia, mastocytosis, tissue remodeling, and impaired barrier function, after PPI therapy, providing compelling evidence that PPIs have therapeutic properties directed at allergic inflammation [13••]. Furthermore, the study identified candidate genes that may predict PPI responsiveness in EoE patients.

The diagnosis of EoE should be based on the conceptual definition that the patient has an “immune/antigen-mediated” disease. PPIs have multiple effects that might provide benefit in both an allergic disease such as EoE and a peptic acid disorder such as GERD. Thus, for any patient who has esophageal symptoms and esophageal eosinophilia, a clinical and/or histological response to PPIs does not rule in GERD, nor does it rule out EoE. Therefore, a trial of PPI therapy might not be suitable for diagnostic purposes. Assessment for the presence of GERD in a patient with esophageal eosinophilia may require further diagnostic studies such as esophageal pH/impedance monitoring. Diagnostic approaches such as an allergy evaluation, novel gene profiling [13••], or additional immunostaining for inflammatory biomarkers [18, 19] might help discern the presence of an allergy-mediated process in a patient with esophageal eosinophilia. In light of recent developments, updates to current guidelines will likely soon follow. Until then, PPI therapy should be regarded largely as a therapeutic option rather than a diagnostic tactic, and high-dose PPI therapy is a reasonable initial option for EoE patients (Fig. 1).




Fig. 1. Algorithm for current therapeutic options in eosinophilic esophagitis (EoE). *eos/hpf* eosinophils per high-power field, *PPI* proton pump inhibitor.

Allergens and dietary therapy

EoE is an allergic disorder [1]. EoE has been tied to atopic diseases such as asthma, allergic rhinitis, and atopic dermatitis. The link between EoE and food allergens was clearly recognized after Kelly and colleagues documented disease remission in children prescribed an elemental diet and disease recrudescence following food reintroduction [20]. Animal studies have employed intraesophageal ovalbumin [21, 22] or peanut extract [23] challenges in mice to induce EoE, emphasizing the role of food allergens. Seasonal variations associated with diagnosis suggest a role for aeroallergens. Recent human data suggest that aeroallergens might be more relevant in adults and older children, documenting 89 % of EoE adults having aeroallergen sensitization [24] and children's aeroallergen sensitization increasing with age [25]. However, there are some conflicting epidemiological data disputing the seasonal trend in EoE incidence [26, 27].

A dietary approach is a widely accepted form of therapy for EoE. There are three general approaches to the dietary therapy: (1) an elemental diet; (2) an empirical elimination diet; and (3) a directed elimination diet. The elemental diet, comprised of an exclusive amino acid-based formula, is the most restrictive approach but is highly effective, with a 90 % remission rate [28••]. The empirical elimination diet strategically excludes food commonly associated with food allergy, such as cow's milk protein, wheat, egg, soy, nuts, and fish, and has demonstrated 72 % efficacy [28••]. The directed elimination diet is based on allergy testing (skin prick testing and/or atopic patch testing). However, current allergic testing methods have limitations and are not reliable in identifying food triggers, and the directed elimination diet approach was less successful, at 45 % efficacy [28••].

There are three stages to the dietary therapy [29]. The first stage achieves disease remission 6–8 weeks after initiation of the diet. The second stage reintroduces previously excluded foods in a stepwise fashion to identify trigger food(s) with endoscopy and histology. Patients typically have one or two culprits identified through this process. The third stage establishes a maintenance regimen, which excludes identified trigger food(s) long-term in order to maintain remission.

Overall, dietary therapy offers EoE patients a relatively safe, long-term option. However, there are several potential challenges that need to be considered. All diets are restrictive and require close monitoring for nutritional deficiencies. Patients require education in food labels and cross-contamination. Factors such as lifestyle restrictions, enteral feeding tube requirement, dietary costs, endoscopic procedural costs, and a tedious reintroduction stage can potentially detract from patient adherence to therapy. For these reasons, dietary therapy should be offered to highly motivated patients, with preference for a six-food elimination diet (SFED), then a directed elimination diet, and reserving the elemental diet for severe or refractory cases (Fig. 1).

Th2 cytokines (IL-5, IL-13, and IL-4)

EoE is considered a hypersensitivity to allergens. The disease tends to fall within the spectrum of T cell-mediated hypersensitivity as opposed to immunoglobulin (Ig) E-mediated hypersensitivity, although both mechanisms are likely involved. In T cell-mediated hypersensitivity, antigen-presenting cells and antigen-specific T cells activate a Th2-predominant inflammatory response. Dendritic cells [30], epithelial cells [31], and eosinophils [32] are all presumed to function in some capacity as antigen-presenting cells in EoE. Straumann and colleagues first discovered that Th2-mediated allergic inflammation was involved in EoE [33]; several studies followed, reflecting elevated expression of Th2 cytokines (interleukin [IL]-5, IL-13, and IL-4) in the esophagus and serum [34–36]. These Th2 cytokines are responsible for the recruitment and activation of eosinophils, mast cells, and basophils.

IL-5, in particular, is known to promote eosinophil proliferation in the bone marrow and to prime eosinophils for cytokine stimulation. Early murine studies established that eosinophil trafficking is IL-5 dependent [37]. IL-5 also led to esophageal remodeling and fibrosis in the mice [38–40]. A few clinical studies have targeted IL-5 with the humanized monoclonal antibodies mepolizumab

and reslizumab. Despite a reduction in peripheral eosinophilia or esophageal eosinophilia, the anti-IL-5 therapies did not achieve symptomatic resolution [41–44]. A recent subanalysis of a pediatric mepolizumab study described a reduction in esophageal mast cells and eosinophil–mast cell couplets in responders [45]. Thus, IL-5 holds a central role in eosinophil and mast cell function in EoE, and continues to be a viable therapeutic target.

The EoE transcriptome determined by genome-wide microarray discovered many IL-13-inducible genes responsible for pathogenesis [34, 46]. IL-13 can induce esophageal epithelial cells to express eotaxin-3, a strong chemoattractant for eosinophils. Remarkably, eotaxin-3 is the most highly upregulated gene (with a 53-fold increase) in the EoE transcriptome [46]. This study also identified a single nucleotide polymorphism (SNP) in the eotaxin-3 gene that is associated with disease susceptibility. Recent studies elaborated how epigenetic DNA methylation might mediate eotaxin-3 regulation [47]. As previously stated, PPIs can decrease IL-13-induced eotaxin-3 expression in esophageal epithelial cells [15•, 16]. Mice with genetic deletion of the eotaxin-3 receptor were protected from allergen-induced EoE [46]. Previous animal studies confirmed that IL-13 facilitates eosinophil recruitment [48]; however, recent studies concluded that IL-13 is not critical, as deletion of IL-13 did not abolish eosinophilia [49]. IL-13 can potentially disrupt the integrity of the epithelial barrier by downregulating epithelial cell differentiation genes such as filaggrin, involucrin, and desmoglein-1 [50, 51•]. Periostin, an extracellular matrix (ECM) protein involved in both fibrogenesis and eosinophil trafficking, is markedly upregulated in esophageal specimens and is regulated by IL-13 as well [52]. IL-13 overexpression in mice induced features of esophageal remodeling [53]. Overall, compelling evidence underscores the prominent effect IL-13 has on disease progression. An RCT tested QAX576, a monoclonal antibody against IL-13, with promising results [54]. QAX576 was well tolerated and reduced intraepithelial eosinophil by 60 %. Expression of EoE transcripts improved. Presently, a phase II, double-blind RCT (clinicaltrials.gov study ID NCT02098473) is evaluating the efficacy and safety of the anti-IL-13 monoclonal antibody RPC4046 in adults with EoE.

Although esophageal IL-4 expression is higher in EoE patients [35, 36], it is still unclear what specific effects are commanded by IL-4. In other allergic disorders, IL-4 induces naïve T cells to differentiate into Th2 cells. IL-4 also facilitates B cell class switching to IgE. In esophageal epithelial cells, IL-4 stimulates eotaxin-3 secretion [15•]. The anti-IL-4 monoclonal antibody dupilumab is already being examined in other conditions, such as asthma and atopic dermatitis, and preparations for a clinical trial in EoE are underway.

Eosinophils

Eosinophils do not normally reside in the esophagus. Eosinophils derive from the bone marrow, where systemic cytokines, such as IL-5, stimulate proliferation. The peripheral eosinophils are then primed for systemic and local chemokines, which ultimately direct eosinophils to the esophagus. Peripheral eosinophils from EoE patients are primed for recruitment with enhanced expression of CRTH2 (the receptor for the chemoattractant prostaglandin D2) [55], intercellular adhesion molecule 1 (ICAM-1) [55, 56], and C-C chemokine

receptor 3 (CCR3, the receptor for eotaxin-3) [57]. In the esophagus, local cytokines activate eosinophils to release eosinophil granule proteins, such as major basic protein-1, eosinophil-derived neurotoxin, eosinophil cationic protein, and eosinophil peroxidase, by cytolytic degranulation [58]. These eosinophil granule proteins injure the esophageal mucosa and can be detected with a novel esophageal string device to assess mucosal inflammation [59].

Therapies aimed at preventing eosinophil recruitment seem promising. An RCT utilized OC000459 to selectively inhibit CRTH2, the receptor for prostaglandin D2, in adults with corticosteroid-refractory EoE [60]. The drug was well tolerated and achieved reductions in esophageal eosinophilia and symptoms. Administration of an antibody against Siglec-F, an eosinophil receptor, decreased eosinophils and remodeling in the esophagi of mice with allergen-induced EoE [61]. Anti-Siglec therapies are being investigated in other human diseases, but currently none are used in EoE.

Thymic stromal lymphopoietin and basophils

Thymic stromal lymphopoietin (TSLP) was brought to the forefront by genome-wide association studies (GWAS) [62, 63] and candidate gene profiling [64•], as SNPs associated with EoE were identified at the gene. It has been speculated that TSLP, an epithelial-derived cytokine, drives allergic inflammation by expanding a distinct basophil population that promotes Th2-mediated inflammation [65]. Noti and colleagues developed an allergen-induced EoE mouse model that delineated a TSLP-basophil axis in which eosinophilic inflammation was dependent on both TSLP and basophils [23]. The investigators also provided translational data correlating TSLP genetic variants with increased basophil numbers in subjects with EoE [23]. In another study, the population of basophils isolated from blood taken from EoE patients expressed a distinct Th2-related functional profile [65]. Additional TSLP studies identified a SNP for the TSLP receptor located on Xp22.3 and Yp11.3, and may account for the male predilection in EoE [64•].

So far, anti-TSLP therapy and anti-basophil therapy have been examined only in murine models [23]. Treatment of mice with allergen-induced EoE with either an anti-TSLP monoclonal antibody or a basophil-depleting CD200R3-specific monoclonal antibody reduced esophageal eosinophilia. The incidence of food impaction in the mice decreased with blockade of either TSLP or basophils.

Invariant natural killer T cells

The role of invariant natural killer T (iNKT) cells has been of particular interest. iNKT cells are a subset of T cells responsive to sphingolipid antigens when presented by CD1d surface molecules. A dietary sphingolipid, such as cow's milk-derived sphingomyelin, when loaded onto a CD1d molecule, induced iNKT cell proliferation and profound Th2 cytokine secretion [66]. Furthermore, mice deficient in CD1d were protected from the allergen-induced EoE [67]. Esophageal biopsies from EoE patients contained high levels of iNKT cells [68, 69]. iNKT cells from active EoE patients produced more Th2 cytokines when activated by milk-derived sphingomyelin, compared with iNKT cells isolated

from control subjects or patients with inactive EoE [68]. Collectively, these data support a prominent role for iNKT cells in driving Th2-mediated inflammation.

iNKT cells may have an etiological role in EoE. Lexmond and colleagues provide compelling evidence proposing that iNKT cells may have an early role in the process of allergic sensitization [70•]. In early life, iNKT cells respond to microbial lipid antigens. When early-life microbial signals are not present, expression of the iNKT cell chemokine CXCL16 is increased, causing persistent accumulation of iNKT cells in the colon and lungs. As a result, these mucosal tissues become susceptible to allergic sensitization as the iNKT cells anticipate lipid antigen presentation. The investigators detected high messenger RNA (mRNA) levels of CXCL16, iNKT cell markers, and CD1d in esophageal biopsies from early-onset EoE patients (aged <6 years at diagnosis) who were highly sensitized to food antigens [70•]. Indeed, early life exposure, such as antibiotic use in infancy, was associated with six times the odds of having EoE [71] and might have sufficiently attenuated early-life microbial signals.

As for therapy, Lexmond and colleagues demonstrated that dietary therapy normalized markers of the CXCL16–iNKT–CD1d axis [70•]. CD1d-deficient mice were protected from allergen-induced EoE [67]. Neutralizing anti-CD1d antibody or anti-human V α 24J α 18 (iNKT cell receptor chain) antibody prevented allergen-induced EoE in mice [69]. Thus, the iNKT cell pathway proves to be a promising novel pathway to target.

Mast cells

Mast cells, similar to eosinophils, contain inflammatory mediators (transforming growth factor β 1 [TGF β 1], IL-4, IL-13, histamine, leukotrienes, tryptase, chymase, and carboxypeptidase A3) that can contribute to EoE pathogenesis and fibrogenesis. Mast cell activation can be initiated in many ways, with the most common being antigen cross-linking of IgE and the high-affinity receptor Fc ϵ RI. Both human and animal studies recognize congruencies between eosinophils and mast cells in EoE [72–77]. A recent study, involving a guinea pig model of EoE, demonstrated that the mast cell mediator prostaglandin D2 induces eosinophil trafficking via D-type prostanoid receptor 2 [77]. Immunostaining for tryptase and IgE illustrated that IgE-bearing mast cells are increased in the epithelium and lamina propria of EoE patients [78]. Mast cells containing tryptase were increased in the esophageal smooth-muscle layer [73]. These mast cells also expressed TGF β 1, which can induce smooth-muscle cell contraction, suggesting that mast cells might mediate esophageal contraction. In animal counterparts, mast cells are localized in the lamina propria and muscularis mucosa of mice with allergen-induced EoE, further supporting the idea that mast cells promote smooth-muscle hypertrophy and govern esophageal function [75].

Previous experiences involving the mast cell stabilizer cromolyn sodium have been rather unsuccessful [1]. Results with the leukotriene receptor antagonist montelukast have been equivocal [1], and there are upcoming trials on montelukast (clinicaltrials.gov study IDs NCT00511316 and NCT01458418). Both topical steroid therapy and dietary therapy have modulated mast cells and mast cell-associated genes [76]. As mentioned previously, the anti-IL-5 monoclonal antibody mepolizumab decreased mast cells and eosinophil-mast cell

couplets in the esophagi of responders, underscoring the intimate relationship between eosinophils and mast cells [45].

EoE and IgE-mediated allergy

Although EoE is considered a food allergy, the relationship between EoE and IgE-mediated food allergy is confounding. To briefly review, IgE-mediated hypersensitivity requires Th2 cells to signal B cell class switching to generate antigen-specific IgE. Cross-linking of antigen, antigen-specific IgE, and Fc receptors on mast cells or basophils activates the release of mediators such as histamine, tryptase, and leukotrienes. IgE-mediated food allergy has been observed in 15–43 % of EoE patients [1]. Food-specific IgE has been detected by skin prick testing with some success in children [79] but with less success in adults [80]. Furthermore, specific IgE to plant allergens, such as birch pollen or profilin, can cross-react with food components in EoE adults [81, 82]. Certainly, IgE-bearing mast cells and B cells are detected at elevated levels in esophageal biopsies from EoE patients [83]. However, EoE is not dependent on IgE-mediated inflammation, as IgE-deficient and B cell-deficient mice continue to have esophageal inflammation [23, 84]. In addition, the anti-IgE monoclonal antibody omalizumab was ineffective in treating subjects with EoE [85, 86].

Interestingly, reports describing EoE development after oral immunotherapy for IgE-mediated food allergy in up to 2.7 % of patients have called for deeper evaluation of the pathophysiology of IgE-mediated allergy and EoE [87, 88]. Although the mechanism of oral immunotherapy is not completely understood, it is speculated that desensitization is achieved by evoking suppressor T cell activity, decreasing specific IgE levels while increasing specific IgG4 levels [89]. A recent study implicates IgG4 involvement in EoE pathogenesis [85]. Patients with EoE had increased total serum levels of IgG4, and the specific-food IgG4 that was detected reacted with common EoE triggers (milk, wheat, eggs, and nuts). Levels of IgG4 were 45-fold higher in esophageal tissue from EoE patients, and dense IgG4 plasma cell infiltration was depicted in the lamina propria. The current research implies that EoE may be an IgG4-associated disease, but further studies are needed to delineate the relationship between IgG4 and EoE.

Epithelial barrier function

The esophageal epithelium is composed of stratified squamous epithelial cells, which form a barrier during health. How allergens reach to the esophagus is unknown; epithelial barrier dysfunction poses a reasonable susceptibility for allergens to enter the esophageal epithelium. In active EoE, histological findings of spongiosis or dilated intercellular spaces indicate impairment in the epithelial barrier [1]. Baseline intraluminal impedance measurement, a marker of mucosal integrity, was lower in EoE patients [90]. Indeed, measurements of permeability and transepithelial electrical resistance in ex vivo tissue biopsies also confirmed barrier dysfunction [51•]. Expression of cell junction and adhesion proteins, such as E-cadherin, claudin-1, zonula occludens-3, and desmoglein-1, was diminished in biopsies [51•, 91, 92]. Genes associated with epithelial differentiation and barrier function, such as involucrin, small proline-rich protein, and filaggrin, were downregulated [50]. However, filaggrin protein expression in

epithelial cells increased after steroid therapy in children [93] and adults [92] with EoE. Lastly, treatment with high-dose esomeprazole improved mucosal integrity in PPI-REE patients [14]. Restoring epithelial barrier function seems to be an appropriate therapeutic parameter to achieve; however, it is still not clear if there is intrinsic barrier dysfunction in EoE patients that precedes inflammation.

Steroid therapy

Both topical and systemic corticosteroids are considered effective therapies for inducing and maintaining remission in EoE, and several controlled trials have been conducted in both children and adults [94]. However, the mechanism of action of steroids is not entirely understood in EoE. As highlighted throughout this review, corticosteroids have pleiotropic effects on immune cells, esophageal cells, and mediators relevant to EoE pathogenesis. The IL-13-induced transcriptome in EoE was reversed with steroid treatment [34]. Steroid treatment downregulated IL-5 gene expression in the human esophagus [95] and attenuated IL-5-induced esophageal inflammation in mice [40]. After steroid therapy, eosinophils from EoE patients had decreased surface marker CD18, which might impair cell adhesion [56]. Expression of mast cell-associated genes was significantly decreased after steroid treatment in EoE patients [76]. Potential indicators that might determine steroid responsiveness include FK506 binding protein 51 gene expression, TGF β 1 genetic polymorphisms, esophageal tryptase, and esophageal eotaxin-3 [96–98].

In the clinical setting, topical steroids are preferred, given their favorable safety profile, while systemic steroids are generally reserved for severe cases. The most common ways of administering corticosteroids topically to the esophagus are swallowed aerosolized fluticasone and oral viscous budesonide. For fluticasone, patients are instructed to hold their breath, puff the inhaler, and then swallow. For oral viscous budesonide, patients are directed to mix the contents of the budesonide respule (0.5 mg/2 mL) with sucralose to create a slurry. In addition, there have been both formal and anecdotal reports describing use of various other viscous agents, such as honey, apple sauce, amino acid-based semisolid, and food thickeners [94]. In general, after topical steroid application, patients are asked to not eat or drink for 30 minutes and are then asked to rinse the medication from the mouth to prevent oral candidiasis. With the exception of esophageal candidiasis and herpes esophagitis, topical steroids are generally well tolerated and less prohibitive in terms of lifestyle. Short-term data have not confirmed adrenal suppression. However, because of the necessity for maintenance therapy, long-term safety data on bone health, growth, and adrenal suppression are needed. The therapeutic effects of topical steroids are largely limited by uneven delivery and penetration into the affected areas of the esophagus. Current and future clinical studies aim to optimize the dose, frequency, formulation, and delivery of corticosteroids in both the induction and maintenance of remission in EoE.

Remodeling, fibrogenesis, and epithelial–mesenchymal transition

The chronic inflammatory nature of EoE will progress to a fibrostenotic disease the longer the disease is left untreated [99, 100]. Outcomes such as food

impactions, fibrotic strictures, esophageal narrowing, mucosal tears, and transmural perforations are all due to esophageal remodeling and fibrosis [1, 101, 102]. Fibrogenesis is part of the normal repair response to epithelial injury, where activated fibroblasts synthesize and organize ECM proteins, such as collagen, fibronectin, and tenascin-C [103]. Once inflammation has subsided and the tissue is repaired, fibroblasts will reorganize the fibrous tissue to restore normal tissue. However, with unrelenting inflammation, excessive deposition of ECM proteins creates fibrosis. Challenges to understanding EoE remodeling are largely due to limitations in diagnostic tools to assess the deeper layers of the human esophagus, where subepithelial fibrosis [74], smooth-muscle hypertrophy, and angiogenesis [104] occur. Several mediators and cells involved in Th2 inflammation will facilitate fibrogenesis. IL-5 promoted collagen deposition [39] and IL-13 overexpression generated features of esophageal remodeling, strictures, and dysmotility in mice [38, 53]. In humans, eosinophils are located throughout the entire thickness of the esophagus, including the muscle layers, and exposure to their products caused esophageal fibroblasts and smooth-muscle cells to secrete ECM proteins, collagen I, and fibronectin [105]. Mast cells residing in the lamina propria and smooth-muscle layer likely contribute to smooth-muscle dysfunction [73, 76]. Both eosinophils and mast cells are potential cellular sources for TGF β 1—a well-known fibrogenic agent.

Epithelial cells have also acquired the means to drive fibrogenesis. Epithelial–mesenchymal transition (EMT) is the process by which epithelial cells lose their epithelial characteristics and gain mesenchymal features of a fibroblast. Staining for vimentin (a mesenchymal marker) and cytokeratin (an epithelial marker) revealed evidence of EMT in the EoE epithelium [106]. TGF β 1 induced EMT by upregulating mesenchymal markers, such as N-cadherin, vimentin, and fibronectin [106]. Tumor necrosis factor- α (TNF- α) and IL-1 β can also induce EMT changes, including acquisition of α -smooth muscle actin (α SMA) and loss of E-cadherin [107]. Epithelial cells that have undergone EMT can signal to nearby fibroblasts to secrete fibrogenic cytokines, which likely precipitate the subepithelial fibrosis seen in EoE [108]. Features of EMT resolved after patients were treated with an elemental diet, SFED, or topical steroids [106].

It is clear that TGF β 1 plays a central role in fibrogenesis and EMT; thus, interrupting TGF β 1 signaling is an attractive therapeutic strategy. Silencing TGF β 1 signaling targets, such as phospholamban [109] and Smad3 [21], has diminished the contraction in vitro and abrogated fibrosis and angiogenesis in mice. There is an ongoing phase II trial looking at the effectiveness of losartan, an angiotensin II receptor blocker, which might reduce TGF β 1, in patients with EoE (clinicaltrials.gov study ID NCT01808196).

Dilation for fibrostenosis

As previously discussed, PPIs, steroids, and dietary therapies can attenuate esophageal inflammation, thereby preventing further fibrogenesis and remodeling while esophageal tissue restores to normal. The ability of any of these therapies to reverse long-term remodeling is arguable and has not been unequivocally demonstrated. Although it is reasonable to first try medical therapy, an esophageal dilation procedure remains the only effective means of mechanically obliterating high-grade fibrostenotic lesions and providing symptomatic

relief. Initially, higher complication rates with esophageal dilation procedures in EoE patients were reported, but, with increased recognition and experience, a recent meta-analysis reported a complication rate of <1 % [110]. Although dilation does not achieve histological improvement, nor does it address the underlying inflammatory process [111], clinical improvement is achieved in 75 % of cases [110]. Without concurrent medical therapy to address the inflammatory process, patients will need repeat dilations. Thus, dilation should probably be considered an adjuvant therapy to a medical therapy (Fig. 1).

Conclusions

New developments in EoE pathogenesis are refining our current therapeutic and management strategies. EoE is now recognized as a chronic allergic inflammatory disease with progression to fibrostenotic disease. The disease warrants early proper diagnosis and long-term maintenance therapy. The diagnosis of EoE should be based on the concept of an allergy-mediated disease with esophageal dysfunction and esophageal eosinophilia (≥ 15 eos/hpf). PPI-REE is likely a continuum of EoE or a similar Th2-mediated allergic process. Thus, PPIs should be considered a therapeutic option for EoE. If patients are PPI nonresponsive, then dietary therapy or steroid therapy could be offered. Dilation should be reserved for severe fibrostenotic lesions. New investigational drugs are on the horizon. Development of genetic markers and biomarkers will help predict responsiveness to treatment and individualize therapy.

Compliance with Ethics Guidelines

Conflict of Interest

Edaire Cheng has received the following grants: American Gastroenterological Association Fellows to Faculty Transition Award, National Institutes of Health (NIH) grant number K12 HD068369-02, NASPGHAN/AstraZeneca Award for Disorders of the Upper GI Tract, American Gastroenterological Association Research Scholar Award, and NIH grant number K08 DK099383-01. Dr. Cheng has also received honoraria from the American Gastroenterological Association.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011;128:3–20.e26. quiz 21–22.
2. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology*. 2007;133:1342–63.

3. Cheng E, Souza RF, Spechler SJ. Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. *Gastroenterol Clin N Am*. 2014;43:243–56.
 4. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut*. 2005;54:710–7.
 5. Hu Y, Liu Z, Yu X, Pasricha PJ, Undem BJ, Yu S. Increased acid responsiveness in vagal sensory neurons in a guinea pig model of eosinophilic esophagitis. *Am J Physiol Gastrointest Liver Physiol*. 2014;307:G149–57.
 6. Krarup AL, Villadsen GE, Mejlgaard E, Olesen SS, Drewes AM, Funch-Jensen P. Acid hypersensitivity in patients with eosinophilic oesophagitis. *Scand J Gastroenterol*. 2010;45:273–81.
 7. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. *Gastroenterology*. 2009;137:1776–84.
 8. Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. *Dig Dis Sci*. 2010;55:1313–9.
 9. Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, Fernandez-Bermejo M, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol*. 2011;9:110–7.
 10. Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RK. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. *Am J Gastroenterol*. 2013;108:366–72.
 11. Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, Levinson S, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. *Am J Gastroenterol*. 2013;108:1854–60.
 12. Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Gebhart JH, et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. *Clin Gastroenterol Hepatol*. 2014;12:2015–22.
 - 13.●● Wen T, Dellon ES, Moawad FJ, Furuta GT, Aceves SS, Rothenberg ME. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. *J Allergy Clin Immunol*. 2014. doi:10.1016/j.jaci.2014.08.043.
 14. van Rhijn BD, Weijenberg PW, Verheij J, van den Bergh Weerman MA, Verseijden C, van den Wijngaard RM, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. *Clin Gastroenterol Hepatol*. 2014;12:1815–1823.e2.
 - 15.● Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. *Gut*. 2013;62:824–32.
- This study elucidates a potential therapeutic anti-inflammatory mechanism of PPI, which may have eosinophil-reducing effects in EoE.
16. Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. *PLoS One*. 2012;7:e50037.
 17. Park JY, Zhang X, Nguyen N, Souza RF, Spechler SJ, Cheng E. Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. *PLoS One*. 2014;9:e101391.
 18. Dellon ES, Chen X, Miller CR, Woosley JT, Shaheen NJ. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. *Am J Gastroenterol*. 2012;107:1503–11.
 19. Dellon ES, Chen X, Miller CR, Fritchie KJ, Rubinas TC, Woosley JT, et al. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. *Am J Gastroenterol*. 2011;106:264–71.
 20. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. *Gastroenterology*. 1995;109:1503–12.
 21. Cho JY, Doshi A, Rosenthal P, Beppu A, Miller M, Aceves S, et al. Smad3-deficient mice have reduced esophageal fibrosis and angiogenesis in a model of egg-induced eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr*. 2014;59:10–6.
 22. Cho JY, Rosenthal P, Miller M, Pham A, Aceves S, Sakuda S, et al. Targeting AMCase reduces esophageal eosinophilic inflammation and remodeling in a mouse model of egg induced eosinophilic esophagitis. *Int Immunopharmacol*. 2014;18:35–42.
 23. Noti M, Wojno ED, Kim BS, Siracusa MC, Giacomini PR, Nair MG, et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. *Nat Med*. 2013;19:1005–13.
 24. Slack MA, Erwin EA, Cho CB, Raveendran R, Phillips G, Ogbogu PU. Food and aeroallergen sensitization in adult eosinophilic esophagitis. *Ann Allergy Asthma Immunol*. 2013;111:304–5.
- This study illustrates that PPI-REE and EoE share virtually the same molecular signature, including expression of several classic allergic inflammation genes, suggesting that PPI-REE is a continuum of EoE. PPI therapy can reverse the allergic inflammation gene expression in PPI-REE.

25. Chadha SN, Wang L, Correa H, Moulton D, Hummell DS. Pediatric eosinophilic esophagitis: the Vanderbilt experience. *Ann Allergy Asthma Immunol*. 2014;113:445–51.
 26. Elias MK, Kopacova J, Arora AS, Dierkhising RA, Enders FT, Katzka DA, et al. The diagnosis of esophageal eosinophilia is not increased in the summer months. *Dysphagia*. 2014. doi:10.1007/s00455-014-9574-1.
 27. Frederickson NW, Bayman L, Valestin J, Redd M, Lee YJ, Soubra M, et al. Lack of seasonal variation in the incidence of eosinophilic oesophagitis in adolescent and adult non-PPI-responsive oesophageal eosinophilia midwestern US populations. *U Eur Gastroenterol J*. 2014;2:69–76.
 - 28.●● Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. *Gastroenterology*. 2014;146:1639–48.
- This is a systematic review and meta-analysis examining the effectiveness of the various dietary approaches in EoE.
29. Gonsalves N, Kagalwalla AF. Dietary treatment of eosinophilic esophagitis. *Gastroenterol Clin N Am*. 2014;43:375–83.
 30. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. *Gastroenterology*. 2002;122:1216–25.
 31. Mulder DJ, Pooni A, Mak N, Hurlbut DJ, Basta S, Justinich CJ. Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis. *Am J Pathol*. 2011;178:744–53.
 32. Le-Carlson M, Seki S, Abarbanel D, Quiros A, Cox K, Nadeau KC. Markers of antigen presentation and activation on eosinophils and T cells in the esophageal tissue of patients with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr*. 2013;56:257–62.
 33. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. *J Allergy Clin Immunol*. 2001;108:954–61.
 34. Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. *J Allergy Clin Immunol*. 2007;120:1292–300.
 35. Straumann A, Kristl J, Conus S, Vassina E, Spichtin HP, Beglinger C, et al. Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. *Inflamm Bowel Dis*. 2005;11:720–6.
 36. Blanchard C, Stucke EM, Rodriguez-Jimenez B, Burwinkel K, Collins MH, Ahrens A, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. *J Allergy Clin Immunol*. 2011;127:208–17. 217.e201–207.
 37. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. *J Immunol*. 2002;168:2464–9.
 38. Mavi P, Rajavelu P, Rayapudi M, Paul RJ, Mishra A. Esophageal functional impairments in experimental eosinophilic esophagitis. *Am J Physiol Gastrointest Liver Physiol*. 2012;302:G1347–55.
 39. Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. *Gastroenterology*. 2008;134:204–14.
 40. Masterson JC, McNamee EN, Hosford L, Capocelli KE, Ruybal J, Fillon SA, et al. Local hypersensitivity reaction in transgenic mice with squamous epithelial IL-5 overexpression provides a novel model of eosinophilic oesophagitis. *Gut*. 2014;63:43–53.
 41. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. *Gut*. 2010;59:21–30.
 42. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs 3rd G, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2012;129:456–63. 463.e451–453.
 43. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. *J Allergy Clin Immunol*. 2006;118:1312–9.
 44. Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. *Gastroenterology*. 2011;141:1593–604.
 45. Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. *J Allergy Clin Immunol*. 2013;131:1576–82.
 46. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest*. 2006;116:536–47.
 47. Lim E, Rothenberg ME. Demethylation of the human eotaxin-3 gene promoter leads to the elevated expression of eotaxin-3. *J Immunol*. 2014;192:466–74.
 48. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. *Gastroenterology*. 2003;125:1419–27.
 49. Niranjana R, Rayapudi M, Mishra A, Dutt P, Dynda S, Mishra A. Pathogenesis of allergen-induced

- eosinophilic esophagitis is independent of interleukin (IL)-13. *Immunol Cell Biol.* 2013;91:408–15.
 50. Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. *J Immunol.* 2010;184:4033–41.
 51. Sherrill JD, Kc K, Wu D, Djukic Z, Caldwell JM, Stucke EM, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. *Mucosal Immunol.* 2014;7:718–29.
- This study investigates the role of epithelial barrier function and how it can potentiate EoE. Desmoglein-1 is a cell adhesion molecule, which is downregulated by IL-13. Downregulation of desmoglein-1 creates barrier disruption and induces an inflammatory transcriptome.
52. Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. *Mucosal Immunol.* 2008;1:289–96.
 53. Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R α 2-inhibited pathway. *J Immunol.* 2010;185:660–9.
 54. Rothenberg ME, Wen T, Greenberg A, Alban O, Enav B, Hirano I, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. *J Allergy Clin Immunol.* 2014. doi:10.1016/j.jaci.2014.07.049.
 55. Johnsson M, Bove M, Bergquist H, Olsson M, Fornwall S, Hassel K, et al. Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy. *J Innate Immun.* 2011;3:594–604.
 56. Lingblom C, Bergquist H, Johnsson M, Sundstrom P, Quiding-Jarbrink M, Bove M, et al. Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells. *Inflammation.* 2014;37:1932–44.
 57. Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, et al. Interplay of adaptive Th2 immunity with eotaxin-3/C-C chemokine receptor 3 in eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2007;45:22–31.
 58. Saffari H, Hoffman LH, Peterson KA, Fang JC, Leiferman KM, Pease 3rd LF, et al. Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis. *J Allergy Clin Immunol.* 2014;133:1728–1734.e1721.
 59. Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. *Gut.* 2013;62:1395–405.
 60. Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. *Allergy.* 2013;68:375–85.
 61. Rubinstein E, Cho JY, Rosenthal P, Chao J, Miller M, Pham A, et al. Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2011;53:409–16.
 62. Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. *Nat Genet.* 2010;42:289–91.
 63. Sleiman PM, Wang ML, Cianferoni A, Aceves S, Gonsalves N, Nadeau K, et al. GWAS identifies four novel eosinophilic esophagitis loci. *Nat Commun.* 2014;5:5593.
 64. Sherrill JD, Gao PS, Stucke EM, Blanchard C, Collins MH, Putnam PE, et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. *J Allergy Clin Immunol.* 2010;126:160–165.e163.
- This study identifies TSLP as a candidate gene involved in mediating Th2 inflammation. It verifies genetic variants of the gene and its receptor associated with the disease.
65. Siracusa MC, Saenz SA, Hill DA, Kim BS, Headley MB, Doering TA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. *Nature.* 2011;477:229–33.
 66. Jyonouchi S, Abraham V, Orange JS, Spergel JM, Gober L, Dudek E, et al. Invariant natural killer T cells from children with versus without food allergy exhibit differential responsiveness to milk-derived sphingomyelin. *J Allergy Clin Immunol.* 2011;128:102–109.e113.
 67. Rajavelu P, Rayapudi M, Moffitt M, Mishra A, Mishra A. Significance of para-esophageal lymph nodes in food or aeroallergen-induced iNKT cell-mediated experimental eosinophilic esophagitis. *Am J Physiol Gastrointest Liver Physiol.* 2012;302:G645–54.
 68. Jyonouchi S, Smith CL, Saretta F, Abraham V, Ruymann KR, Modayur-Chandramouleeswaran P, et al. Invariant natural killer T cells in children with eosinophilic esophagitis. *Clin Exp Allergy.* 2014;44:58–68.
 69. Rayapudi M, Rajavelu P, Zhu X, Kaul A, Niranjan R, Dynda S, et al. Invariant natural killer T-cell neutralization is a possible novel therapy for human eosinophilic esophagitis. *Clin Trans Immunol.* 2014;3:e9.
 70. Lexmond WS, Neves JF, Nurko S, Olszak T, Exley MA, Blumberg RS, et al. Involvement of the iNKT cell pathway is associated with early-onset eosinophilic esophagitis and response to allergen avoidance therapy. *Am J Gastroenterol.* 2014;109:646–57.
- This study describes the iNKT cell pathway and identify a central role that iNKT cells may play in the early process of allergic sensitization in EoE.
71. Jensen ET, Kappelman MD, Kim HP, Ringel-Kulka T, Dellon ES. Early life exposures as risk factors for pediatric eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2013;57:67–71.

72. Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, et al. Involvement of mast cells in eosinophilic esophagitis. *J Allergy Clin Immunol.* 2010;126:140–9.
73. Aceves SS, Chen D, Newbury RO, Dohil R, Bastian JF, Broide DH. Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF- β 1, and increase esophageal smooth muscle contraction. *J Allergy Clin Immunol.* 2010;126:1198–1204.e1194.
74. Chehade M, Sampson HA, Morotti RA, Magid MS. Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2007;45:319–28.
75. Niranjana R, Mavi P, Rayapudi M, Dynda S, Mishra A. Pathogenic role of mast cells in experimental eosinophilic esophagitis. *Am J Physiol Gastrointest Liver Physiol.* 2013;304:G1087–94.
76. Hsu Blatman KS, Gonsalves N, Hirano I, Bryce PJ. Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. *J Allergy Clin Immunol.* 2011;127:1307–1308.e1303.
77. Zhang S, Wu X, Yu S. Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil trafficking into the esophagus. *Dis Esophagus.* 2014;27:601–6.
78. Mulder DJ, Mak N, Hurlbut DJ, Justinich CJ. Atopic and non-atopic eosinophilic oesophagitis are distinguished by immunoglobulin E-bearing intraepithelial mast cells. *Histopathology.* 2012;61:810–22.
79. Spergel JM, Brown-Whitehorn TF, Cianferoni A, Shuker M, Wang ML, Verma R, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. *J Allergy Clin Immunol.* 2012;130:461–467.e465.
80. Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, Porcel-Carreno SL, Jimenez-Timon S, Hernandez-Arbeiza FJ. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. *J Allergy Clin Immunol.* 2012;130:1200–2.
81. Simon D, Straumann A, Dahinden C, Simon HU. Frequent sensitization to *Candida albicans* and profilins in adult eosinophilic esophagitis. *Allergy.* 2013;68:945–8.
82. van Rhijn BD, van Ree R, Versteeg SA, Vlieg-Boerstra BJ, Sprickelman AB, Terreehorst I, et al. Birch pollen sensitization with cross-reactivity to food allergens predominates in adults with eosinophilic esophagitis. *Allergy.* 2013;68:1475–81.
83. Vicario M, Blanchard C, Stringer KF, Collins MH, Mingler MK, Ahrens A, et al. Local B cells and IgE production in the oesophageal mucosa in eosinophilic esophagitis. *Gut.* 2010;59:12–20.
84. Mishra A, Schlotman J, Wang M, Rothenberg ME. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. *J Leukoc Biol.* 2007;81:916–24.
85. Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. *Gastroenterology.* 2014;147:602–9.
86. Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. *Eur J Pediatr.* 2011;170:1471–4.
87. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. *Ann Allergy Asthma Immunol.* 2014;113:624–9.
88. Hsieh FH. Oral food immunotherapy and iatrogenic eosinophilic esophagitis: an acceptable level of risk? *Ann Allergy Asthma Immunol.* 2014;113:581–2.
89. Keet CA, Wood RA. Emerging therapies for food allergy. *J Clin Invest.* 2014;124:1880–6.
90. van Rhijn BD, Kessing BF, Smout AJ, Bredenoord AJ. Oesophageal baseline impedance values are decreased in patients with eosinophilic oesophagitis. *U Eur Gastroenterol J.* 2013;1:242–8.
91. Abdunour-Nakhoul SM, Al-Tawil Y, Gyftopoulos AA, Brown KL, Hansen M, Butcher KF, et al. Alterations in junctional proteins, inflammatory mediators and extracellular matrix molecules in eosinophilic esophagitis. *Clin Immunol.* 2013;148:265–78.
92. Katzka DA, Tadi R, Smyrk TC, Katarya E, Sharma A, Geno DM, et al. Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol.* 2014;12:1824–1829.e1.
93. Matoso A, Mukkada VA, Lu S, Monahan R, Cleveland K, Noble L, et al. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. *Mod Pathol.* 2013;26:665–76.
94. Contreras EM, Gupta SK. Steroids in pediatric eosinophilic esophagitis. *Gastroenterol Clin N Am.* 2014;43:345–56.
95. Lucendo AJ, De Rezende L, Comas C, Caballero T, Bellon T. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. *Am J Gastroenterol.* 2008;103:2184–93.
96. Caldwell JM, Blanchard C, Collins MH, Putnam PE, Kaul A, Aceves SS, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. *J Allergy Clin Immunol.* 2010;125:879–888.e878.
97. Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. *Allergy.* 2010;65:109–16.
98. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, et al. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. *Clin Gastroenterol Hepatol.* 2014. doi:10.1016/j.cgh.2014.07.034.
99. Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows that

- eosinophilic esophagitis is a progressive fibrostenotic disease. *Gastrointest Endosc.* 2014;79:577–585.e574.
100. Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology.* 2013;145:1230–1236.e1231–1232.
101. Hirano I, Aceves SS. Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. *Gastroenterol Clin N Am.* 2014;43:297–316.
102. Fontillon M, Lucendo AJ. Transmural eosinophilic infiltration and fibrosis in a patient with non-traumatic Boerhaave's syndrome due to eosinophilic esophagitis. *Am J Gastroenterol.* 2012;107:1762.
103. Cheng E, Souza RF, Spechler SJ. Tissue remodeling in eosinophilic esophagitis. *Am J Physiol Gastrointest Liver Physiol.* 2012;303:G1175–87.
104. Persad R, Huynh HQ, Hao L, Ha JR, Sergi C, Srivastava R, et al. Angiogenic remodeling in pediatric eosinophilic esophagitis is associated with increased levels of VEGFA, angiogenin, IL-8 and activation of the TNF- α -NF κ B pathway. *J Pediatr Gastroenterol Nutr.* 2012;55:251–60.
105. Rieder F, Nonevski I, Ma J, Ouyang Z, West G, Protheroe C, et al. T-helper 2 cytokines, transforming growth factor beta1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis. *Gastroenterology.* 2014;146:1266–1277.e1261–1269.
106. Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. *J Allergy Clin Immunol.* 2012;129:1387–1396.e7.
107. Muir AB, Dods K, Noah Y, Toltzis S, Chandramouleeswaran PM, Lee A, et al. Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. *Exp Cell Res.* 2015;330:102–10.
108. Muir AB, Lim DM, Benitez AJ, Modayur-Chandramouleeswaran P, Lee AJ, Ruchelli ED, et al. Esophageal epithelial and mesenchymal cross-talk leads to features of epithelial to mesenchymal transition in vitro. *Exp Cell Res.* 2013;319:850–9.
109. Beppu LY, Anilkumar AA, Newbury RO, Dohil R, Broide DH, Aceves SS. TGF- β 1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis. *J Allergy Clin Immunol.* 2014;134:1100–1107.e4.
110. Moawad FJ, Cheatham JG, DeZee KJ. Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. *Aliment Pharmacol Ther.* 2013;38:713–20.
111. Schoepfer AM, Gonsalves N, Bussmann C, Conus S, Simon HU, Straumann A, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. *Am J Gastroenterol.* 2010;105:1062–70.